Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.